Separate terms with OR to return results that match either term.
 
Clear All

716 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date (Ascending) Status
NA Vemurafenib Zelboraf 240 mg Chemotherapy Enzyme Inhibitor BRAF Yes 2011 In Use
NA venetoclax Venclexta 10 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
NA venetoclax Venclexta 50 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
NA venetoclax Venclexta 100 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
J9360 Vinblastine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1965 Jan. 1, 1986 In Use
J9370 Vincristine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan. 1, 1986 In Use
J9390 Vinorelbine Navelbine 10 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1994 Jan. 1, 1996 In Use
NA Vismodegib Vismodegib 150 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2012 In Use
NA Vorinostat Erivedge 100 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2006 In Use
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan. 1, 2014 In Use
J8999 Chemotherapy - non specific Prescription drug, oral, chemotherapeutic NOS NA Chemotherapy Yes In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan. 1, 2019 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan. 1, 2014 In Use
J9015 Aldesleukin Proleukin Per single vial (1 vial = 22 million IU) Immunotherapy Cytokine Interleukin-2 No 1992 Oct. 1, 1996 In Use
J0202 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan. 1, 2016 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct. 1, 2017 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct. 1, 2016 In Use
C9257 Bevacizumab Avastin 0.25 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan. 1, 2010 In Use
J9035 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Jan. 1, 2005 In Use
C9449 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 April 1, 2015 In Use
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan. 1, 2016 In Use
J9042 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan. 1, 2013 In Use
J9055 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Jan. 1, 2005 In Use
J9415 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jan. 1, 2017 In Use

Found 716 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.